Pfizer Corporation

Frank J Urban

Brian C Vanderplas

Ravi Mysore Shanker

Dennis Michael Godek

Charles W Murtiashaw

Joel Michael Hawkins

Keith Michael DeVries

Jeffrey W Raggon

Sally Gut Ruggeri

Jennifer L Rutherford

Teresa M Makowski

John Charles Kath

Vytautas J Jasys

Bernard S Moore

Zhengong Bryan Li

V John Jasys

This invention relates to methods and intermediates useful for the synthesis of pyrrolo[2,3-d]pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-{(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.

Pyrrolo[2,3-d]pyrimidine derivatives: their intermediates and synthesis

Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis

This invention relates to dihydroxyhexanoic acid derivatives and their intermediates, as well as to methods of preparing such compounds. Additionally, present invention relates to removing a protecting group from a protected amine wherein the method comprises reacting the protected amine with phosphoric acid.

Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making

The invention concerns a method of preparing an 8-cyclopentyl-6-ethyl-3-&lsqb;substituted&rsqb;-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacene compound of the formula:

Process for preparing 8-cyclopentyl-6-ethyl-3-&lsqb;substituted&rsqb;-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein

The instant invention relates to intermediates of Formula II, ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, ##STR2## and enantiomers thereof, wherein R.sup.2, R.sup.3 and R.sup.4 are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent .beta..sub.3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the .beta..sub.3 adrenergic receptor agonist using the compounds of Formula II and Formula III.

Process and intermediates for a .beta..sub.3 -adrenergic receptor agonist

An efficent synthesis of furan sulfonamide compounds of formula ##STR1## comprising reacting a compound of formula 11 with a Grignard reagent in a reaction inert solvent, wherein R' is (C.sub.1 -C.sub.6)alkyl. The compound of formula II is prepared by reacting a compound of formula III with a compound of formula IV wherein R' is (C.sub.1 -C.sub.6)alkyl with a chorinating reagent and an acid scaverger in an inert solvent. The invention also includes a novel compound of the formula ##STR2## wherein R' is (C.sub.1 -C.sub.6)alkyl and Q is halo, hydroxy or amino.

Efficient synthesis of furan sulfonamide compounds useful in the

Process and intermediates for preparing

Processes and intermediates for preparing 3-amino-benzo(b)azepinones

Process and intermediates for bis-aza-bicyclic anxiolytic agents

Process for the preparation of a dialkyl trans-piperidine-2,5-dicarboxylate from a corresponding dialkyl cis-piperidine-2,5-dicarboxylate via a trans-substituted pyridine derivative of the formula ##STR1## wherein R is a (C.sub.1 -C.sub.3)alkyl group.

Process for preparing trans-piperidine-2,5-dicarboxylates

(C.sub.1 -C.sub.3)Alkyl-4,6,7,8,9,9a-hexahydro-2H,3H-pyrido[1,2-a]pyrazin-1-one-7-c arboxylate esters, important precursors to certain bis-aza-bicyclic anxiolytics, can be prepared from di(C.sub.1 -C.sub.3)alkyl cis-piperidine-2,5-dicarboxylate starting material by a new process via a new class of intermediates, di(C.sub.1 -C.sub.3)alkyl cis-N-(2-(phthalimido)ethyl)piperidine-2,5-dicarboxylates. In the process, the starting material is reacted with either 2-(phthalimido)ethyl triflate or 2-(phthalimido)acetaldehyde to form the new intermediate, which can then be cyclized to the aforementioned precursor.

Process and intermediate for certain bis-aza-bicyclic anxiolytic agents

A process for preparing the compound of the formula ##STR1## which comprises treating a compound of the formula ##STR2## wherein R.sup.2 is hydrogen, CN or CO.sub.2 R.sup.1 and R.sup.1 is hydrogen or (C.sub.1 -C.sub.6)alkyl with a reducing agent with the proviso that when R.sup.2 is CN or CO.sub.2 R.sup.1 and R.sup.1 is (C.sub.1 -C.sub.6)alkyl the product of the reduction is heated with an acid. Compounds of formula II wherein R.sup.2 is CN or CO.sub.2 R.sup.1 and R.sup.1 is (C.sub.1 -C.sub.6)alkyl or R.sup.2 is hydrogen and R.sup.1 is (C.sub.1 -C.sub.6)alkyl or hydrogen. The compound of formula VII R.sup.1 is (C.sub.1 -C.sub.6)alkyl. The compound of formula III. The compound of formula I is useful in the treatment of psychotic disorders.

Processes and intermediates for the preparation of

Intermediates and a stepwise process for the conversion of D-methionine or certain of its derivatives to optically active compounds of the formula ##STR1## wherein R is (C.sub.1 -C.sub.3)alkyl, phenyl or tolyl. The latter compounds are in turn useful as an intermediate in the preparation of penem antibiotic 5R,6S-6-(1R-hydroxyethyl)-2-(1R-oxo-3S-thiolanylthio)-2-penem-3-carboxylic acid and corresponding pharmaceutically acceptable salts and esters.

Growing community of inventors

Waterford, CT, United States of America

Frank J Urban